Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. - Wikidata - wikimedia - TriplyDB

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

http://www.wikidata.org/entity/Q37334469

about

Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.Precision medicine for disease modification in Parkinson disease.Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease.

P2860

Q33734563-ADC19297-9313-4C3D-B3E0-27B524E4D407 Q33783000-C9B903FF-C8B5-45F4-817F-5170BE0DBF3B Q36474039-1AC29862-62AF-4C48-8117-DFE4286EE719 Q39096323-4F23DC9B-81DC-432A-A565-DAE85586EE0D Q52640400-24FD0351-10D3-4FCA-B27B-3692FA728C96

P2860

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

http://www.wikidata.org/entity/Q37334469

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 October 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

@en

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

@nl

type

label

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

@en

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

@nl

prefLabel

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

@en

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

@nl

P1433

Q37334469-2C41CD70-6F1A-4EF5-B481-D764D345CFAB

P1476

Q37334469-F797508B-7F6C-4F86-862E-CE27D89510D1

P2093

Q37334469-19DD5BFF-D58D-4944-B311-4F8DF32D4BDB

Q37334469-3D473B12-3784-44FF-B6A4-54FFE52F0E99

Q37334469-6113C7A9-F36E-47DE-AE52-1162BB28DAD3

Q37334469-665C2639-D4AB-43DD-9283-CB91D80E6721

Q37334469-6FFEC0C0-C994-43C1-8590-96585F443537

Q37334469-7077FCE8-BC8B-4534-AB2D-5A07C0A86062

Q37334469-732FE1C0-FDB6-4661-BB94-DA45EF4E9E4B

Q37334469-7834CD60-3488-4B05-8C2F-07E7AF36FC3D

Q37334469-796DC21A-EAEA-4B21-BE2B-089E13AF688C

Q37334469-9C076562-694F-4B7E-96C8-EA016C207D80

P2860

Q37334469-0B799420-D73D-4242-B057-F1D83F388B38

Q37334469-19D8008F-40E1-4C97-BDC5-E9360A670D5A

Q37334469-1E365C10-55D3-4A93-AD78-1C0016851AEB

Q37334469-20BDBA9E-7982-443A-8687-3EA1C4F2884E

Q37334469-217661CD-1C29-40D7-8832-982D115C312F

Q37334469-29C18B90-F23C-4B13-BAC6-C22AFEBC19F7

Q37334469-3009AA5D-075A-4194-BC00-BF1D6FA6952D

Q37334469-3097734E-E845-4FBE-AFDC-17F7FC3C23D1

Q37334469-35D725ED-1BC2-46F6-ABE2-B64B09B1B9FB

Q37334469-3C8FB70A-F912-4531-ABD8-43D07610EA8F

P304

Q37334469-7618B61E-EC41-4D0E-90B1-55EF0D76B8E4

P31

Q37334469-FA8D6A69-E81A-4EFF-9209-C94237C3C230

P356

Q37334469-87C5E280-1546-4614-86E7-F32F064FD194

P433

Q37334469-F8AFD292-14B3-4765-8A0D-174361A8AC67

P478

Q37334469-E22A9BDC-903D-46FC-8EA1-56F312133E9F

P50

Q37334469-321145F4-08F9-426C-80D4-88880F2B8575

P577

Q37334469-6FA32AF3-4B38-4B19-854A-5D4E6856BE37

P698

Q37334469-8F813CD5-185E-4E80-B56A-EB9C3B92D466

P921

Q37334469-7F8C17DD-7429-44C6-95A6-2DC400B5EBFD

Q37334469-DE42058F-DDDC-4B9B-B583-F86EB9E4A10A

P932

Q37334469-E172734B-E73D-4873-AE4F-6C86E6B77692

P356

P1433

Journal of Parkinson's disease

P1476

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

@en

P2093

Allison K Graebner

http://www.w3.org/2001/XMLSchema#string

Bernard Ravina

http://www.w3.org/2001/XMLSchema#string

Cornelia Kamp

http://www.w3.org/2001/XMLSchema#string

David K Simon

http://www.w3.org/2001/XMLSchema#string

G Webster Ross

http://www.w3.org/2001/XMLSchema#string

Joanne Clark-Matott

http://www.w3.org/2001/XMLSchema#string

John C Morgan

http://www.w3.org/2001/XMLSchema#string

Jordan Elm

http://www.w3.org/2001/XMLSchema#string

Liana Baker

http://www.w3.org/2001/XMLSchema#string

NINDS NET-PD Investigators

http://www.w3.org/2001/XMLSchema#string

P2860

PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease

Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study

Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease

Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

Critical appraisal of four IL-6 immunoassays

Mitochondria, oxidative damage, and inflammation in Parkinson's disease.

Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum

Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease.

P304

731-736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JPD-150666

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Marina Elena Emborg

P577

2015-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26444095

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5061495

http://www.w3.org/2001/XMLSchema#string